Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.

Author: FujitaYuka, IsozakiMitsuhiro, KanedaHiroyasu, KatoTerufumi, NakagawaKazuhiko, NihoSeiji, NishioMakoto, NogamiNaoyuki, TakahashiToshiaki, TsujiFumito, WadaShinsuke, WilnerKeith, YamamotoNoboru, YoshidaMizuki

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Dacomitinib was more effective than gefitinib in Japanese patients with EGFR-positive advanced NSCLC. PFS was longer with dacomitinib than gefitinib (HR 0.544, P=0.0327). The most common Grade 3 AEs were dermatitis acneiform with dacomitinib (27.5%) and increased alanine aminotransferase with gefitinib (12.2%). Dacomitinib was more likely to lead to dose reduction (85.0%) than gefitinib (24.4%). The incidence and severity of diarrhea, dermatitis acneiform, stomatitis and paronychia were reduced after dacomitinib dose reductions.
Paper Details　
Original Abstract of the Article :
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of first-line oral dacomitinib 45 mg compared with oral gefitinib 250 mg, each once dail...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226281/

データ提供：米国国立医学図書館（NLM）

Dacomitinib: A Promising First-Line Treatment for EGFR-Positive Advanced NSCLC in Japanese Patients

Non-small cell lung cancer (NSCLC) is a serious and complex disease, with targeted therapies playing a crucial role in its management. This study evaluates the efficacy and safety of dacomitinib, an EGFR inhibitor, as a first-line treatment for Japanese patients with EGFR-activating mutation-positive advanced NSCLC. The researchers sought to determine if dacomitinib could provide a beneficial and well-tolerated treatment option in this population.

Dacomitinib: A Superior Treatment Option for EGFR-Positive NSCLC

The study demonstrated that dacomitinib was more effective than gefitinib in prolonging progression-free survival (PFS) in Japanese patients with EGFR-positive advanced NSCLC. While both drugs showed efficacy, dacomitinib provided a statistically significant improvement in PFS. The study also found that dacomitinib was well-tolerated, with the most common adverse events being dermatitis acneiform and dose reductions. These findings suggest that dacomitinib could be a promising first-line treatment option for Japanese patients with EGFR-positive advanced NSCLC.

Personalized Medicine: Tailoring Treatment for Individual Needs

This research highlights the growing importance of personalized medicine in cancer treatment. The study's findings emphasize the need to consider patient-specific factors, such as ethnicity, in selecting the most effective and well-tolerated treatment options. Just as a desert traveler adapts their journey to the terrain, oncologists must tailor treatment strategies to meet the unique needs of each individual patient.

Dr. Camel's Conclusion

This research, like a caravan traversing a diverse desert landscape, explores the efficacy of dacomitinib as a first-line treatment for EGFR-positive NSCLC in Japanese patients. The study's findings, like a hidden oasis of hope, reveal the potential of dacomitinib to provide a superior treatment option for this challenging disease. By embracing personalized medicine and considering patient-specific factors, we can pave the way for more effective and individualized cancer treatments.

Date :
  1. Date Completed 2020-06-01
  2. Date Revised 2020-06-01
Further Info :

Pubmed ID

32159882

DOI: Digital Object Identifier

PMC7226281

Related Literature

Article Analysis
・Side Effects of dacomitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.